Published On : 08 Jun 2018
Regenerative medicine promises to carve new paradigm in healthcare, showcasing possibilities of resolving strong unmet demands across the world. In the recent past, there has been a radical expansion in the interdisciplinary area of regenerative medicine, which is poised to alter the healthcare sector by changing fundamental science over to various technologies such as stem cell. Primarily a mass of undifferentiated cells that have the capability to divide numerous times, they can be bifurcated into skin cells, blood cells, chondrocytes, heart cells, neurons, and osteocytes, depending on environments. Stem cells exhibit striking characteristics including self-renewal, unspecialized nature, and dedifferentiation, and the market for the same is expanding at a formidable CAGR, according to a fresh business intelligence study offered on QYResearchReports.com. The report targets audiences such as manufacturers and vendors of stem cell assays, clinical research and consulting firms, and healthcare institutions.
A number of factors are poised to augment the demand in the global adult stem cell assay market, such as rising incidence of target indications, increasing availability of funds for stem cell research, and growth of the end-use industries. Additionally, technological advancements such as the advent of novel stem cell products and microfluidics are expected to open vast new opportunities for the players in the near future. However, complexities pertaining to antibody and reagent development, consistent entry of new players and them being able to sustain a piece of shares, ethical issues with embryonic stem cell research, and high cost of the analytical instruments and reagents are some of the restraints curtailing the progress of the market. Nevertheless, emerging economies such as India, Japan, and China are expected to expand demand horizons substantially in the near future.
Request for more detailed information (TOC And Sample): https://www.qyresearchreports.com/sample/sample.php?rep_id=1791538&type=S
Going forward, microfabrication-assisted technologies that can be droplet-based, microfluidics-based, microwell-based analysis systems, and bead-based multiplex assays are anticipated to pave new revenue avenues in the market for adult stem cell assay. Based on product type, the market has been segmented into isolation and purification, viability or cytotoxicity, cell identification, apoptosis, function, differentiation, and proliferation. Application-wise, the market for adult stem cell assays has been bifurcated into clinical research, drug discovery and development, and regenerative medicine and therapy development.
The developed country of the U.S. continuous to formulate for the most prominent chunk of demand for adult stem cell assays, which is a reflection of a number of pioneering healthcare companies housed in the North American leaders. That being said, emerging economies such as China and India constitute for more than one third of the global population and are expected to transform as highly profitable.
Merck KGaA, GE Healthcare, Thermo Fisher Scientific, STEMCELL Technologies Inc., Promega Corporation, Bio-Techne Corporation, Hemogenix, Cellular Dynamics International Inc., Cell Biolabs Inc., and Bio-Rad Laboratories, Inc. are some of the notable companies operating in this market.
Top Trending Report: